Clinical Trials · NCT02274740

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

TerminatedPhase 2Lixisenatide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Sanofi
Enrollment
2
Start date
Apr 2015
Locations
See registry
Primary endpoint
Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)
View Lixisenatide compound reference